



Pharmacokinetics of Daily Nevirapine in Neonates at High Risk of HIV Acquisition

Tim R. Cressey^{1,2}, Baralee Punyawudho³, Saik Urien⁴, Gonzague Jourdain^{1,2,5}, Sophie Le Coeur^{1,2,6}, Nicole Ngo-Giang-Huong^{1,2,5}, Pra-ornsuda Sukrakanchana¹, Suporn Koetsawang⁷, Marc Lallemand^{1,2,5} for the PHPT-5 study team.

Tim R. Cressey
Program for HIV Prevention and Treatment
Faculty of Associated Medical Sciences
Chiang Mai University
Chiang Mai, 50200, Thailand
tim.cressey@chulabp.org
t.cressey@hsph.harvard.edu

¹PHPT/IRD 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand, ²Department of Immunology & Infectious Diseases, Boston, Harvard T.H. Chan School of Public Health, MA, USA, ³Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand; ⁴EAU08 Université Paris Descartes, Sorbonne Paris Cité, Paris, France; ⁵Institut de Recherche pour le Développement (IRD) UMI 174-PHPT, Marseille, France; ⁶Institut d'Etudes Démographiques, Paris, France; ⁷Family Health Research Center, Mahidol University, Bangkok, Thailand;

Background

- Infants born to HIV-infected women with no or a short duration of antiretroviral treatment during pregnancy are at high-risk of perinatal transmission.
- Nevirapine (NVP) is a key component of antiretroviral (ARV) prophylaxis for newborns at high risk of intrapartum HIV infection.
- For infants diagnosed HIV positive at birth, 'therapeutic' dosing of nevirapine is necessary
- Thus, it is important to determine the optimal prophylaxis dose of NVP in newborns at High Risk of HIV Acquisition and the therapeutic dose for HIV-infected infants identified at birth

Objective

- To develop a population pharmacokinetic (PK) model to describe NVP concentrations in infants from birth through the first 2 weeks of life.

Study Design & Methods

Study Design and Population

- Infants were enrolled in an adaptive single-arm, multicenter trial in Thailand assessing 'Perinatal Antiretroviral Intensification' to prevent mother-to-child transmission of HIV in pregnant women with <8 weeks of triple ARV treatment prior to delivery (ClinicalTrials.gov NCT01511237).

ARV Prophylaxis

- Intensification consisted of maternal single-dose NVP (sd-NVP) during labor and an infant 2-week course of AZT+3TC+ NVP, followed by AZT+3TC for 2 weeks. NVP dosing was 2 mg/kg for 7 days, then 4 mg/kg for 7 days.

PK Sampling

- Infant blood samples were drawn from the umbilical cord at birth, on the first day of life and at 2 weeks.

Drug Level Measurement and PK analysis

- Measurement of NVP plasma drug levels were performed by a validated HPLC assay (lower limit of quantitation of 0.050 mg/L)
- Population means and variances of NVP PK parameters were estimated using non-linear mixed effects regression models (NONMEM Version VII).
- Infant characteristics (weight, sex, age, postnatal age) were evaluated for their inclusion in the model.
- The validity of the final model was evaluated using a visual predictive check and bootstrap re-sampling techniques (400 Bootstrap analyses).
- Monte Carlo simulations were performed to estimate the probability of achieving target NVP trough concentrations (C₂₄) for prophylaxis (>0.10 mg/L) and for therapeutic efficacy (>3.0 mg/L) during the first 2 weeks of life.

The study was approved by the Ethics Committees (EC) at the Ministry of Public Health, Thailand; the Faculty of Associated Medical Sciences, Chiang Mai University, and local hospital ECs.

Results

- Sixty two infants were included in this analysis:

Table 1: Infant Characteristics at Birth

Median (range)	(n=62)
Gender	
Male	35 (56%)
Female	27 (44%)
Race/Ethnicity: Asian	62 (100%)
Gestational Age at Birth (wks)	38.6 (35.7-41.7)
Weight (kg)	2.9 (2.3-3.7) kg

Nevirapine Population Pharmacokinetic Model

- NVP pharmacokinetics was best described by a one compartment model with first order absorption and elimination.
- Body weight influenced NVP apparent oral clearance (CL/F) and volume of distribution (Vd/F).
- Goodness of fits plots of the NVP model are shown in Figure 1 and evaluation by visual predictive check is shown in Figure 2
- Final population estimates of NVP are presented in Table 2

Figure 1: Goodness-of-fit plots of the final NVP model




Figure 2: Visual predictive check for NVP population PK model. Lines represent the predicted population 5%, 50% and 95% percentiles and shaded areas are the 90% CIs. Observed concentrations from the infants are superimposed.

Table 2: Final NVP population pharmacokinetic parameter estimates

NVP PK Parameters	Final Model		Bootstrap ^a	
	Estimate	RSE (%)	Median	5th - 95th percentile
CL/F (L/h/3kg)	0.144	10.2	0.147	0.114 - 2.02
θ_{WT-CL}	4.00	21.1	3.93	2.62 - 5.70
Vd/F (L/3kg)	3.67	30.8	3.51	1.90 - 6.69
θ_{WT-Vd}	4.59	25.7	4.66	2.00 - 8.10
Ka (h ⁻¹)	0.23	55.1	0.21	0.10 - 0.79
Inter-individual variability (IIV)				
IIV (CL/F)	0.51	12.3	0.52	0.40 - 1.02
IIV (Vd/F)	1.48	16.1	1.32	0.70 - 2.05
IIV (Ka)	1.00	49.3	1.00	0.01 - 2.2
Residual Variability				
σ (Proportional)	0.12	39.7	0.12	0.03 - 0.2

- RSE%: relative standard error (standard error of estimate / estimate*100);


Simulation of Prophylaxis NVP dosing in Newborns

- Simulations of NVP trough concentration for a 3 kg infant receiving 2 mg/kg NVP once daily for 7 days and then 4 mg/kg for 7 days is shown in Figure 3a. Based on simulations for a 3 kg infant, without maternal sd-NVP, >88% would have a NVP C₂₄ >0.1 mg/L after 24 hours through 2 weeks.

- Simulations of NVP trough concentration for a 3 kg infant receiving the WHO recommended 15 mg once daily dose is shown in Figure 3b; it was predicted that >92% of infants would have a NVP C₂₄ >0.1 mg/L after 24 hours.

Figure 3: Simulated NVP C₂₄h in newborns following (a) 2 mg/kg OD at birth, then 4 mg/kg OD at day 7 to 14 (PHPT-5 dosing); (b) 15 mg once daily from birth until days 14 of life (WHO guidelines).

[Note: Middle line is the 50th percentile, lower/upper solid lines represent the 5th & 95th percentiles of the simulated data]



Median (5th, 95th percentile) NVP C₂₄:
At 24 hour : 0.41 (0.03-1.2) mg/L
At Day 14 : 1.24 (0.05-3.5) mg/L

Median (5th, 95th percentile) NVP C₂₄:
At 24 hour : 1.03 (0.06-3.2) mg/L
At Day 14 : 1.62 (0.05-4.6) mg/L


Simulation of Therapeutic dosing in Newborns

- Assuming linear kinetics, simulations of NVP trough concentration for a 3 kg infant receiving 6 mg/kg NVP twice daily for 14 days is shown in Figure 4a. It was predicted that 72% of infants would have a C₂₄ >3.0 mg/L at 48 hours and 76% at 2 weeks.

- With 8 mg/kg twice daily the C₂₄ was predicted to be >3.0 mg/L in 81% of infants at 48 hours and 86% at 2 weeks (Figure 4b).

Figure 4: Simulated NVP C₂₄h in newborns following (a) 6 mg/kg (b) 8 mg/kg twice daily from birth until days 14 of life.

[Note: Middle line is the 50th percentile, lower/upper solid lines represent the 5th & 95th percentiles of the simulated data]



Median (5th, 95th percentile) NVP C₂₄:
At 48 hour : 4.7 (0.8-12.9) mg/L
At Day 14 : 4.9 (1.1-12.5) mg/L

Median (5th, 95th percentile) NVP C₂₄:
At 48 hour : 6.3 (1.0-17.1) mg/L
At Day 14 : 6.5 (1.4-16.6) mg/L

Conclusion

- The escalating NVP dose in PHPT-5 and the WHO single dose approach rapidly achieve and maintain target prophylactic concentrations over the first 2 weeks of life.
- Therapeutic NVP doses of 6 to 8 mg/kg twice daily should be studied in infants initiating treatment within the first few days of life.

Acknowledgements

- The authors wish to thank the subjects that participated in the PHPT-5 trial and the study staff conducting the protocol at the sites. This study was supported by the National Institute of Child Health and Human Development (NICHD), National Institutes of Health, USA. Grants number: R01HD052461 R01HD056953